Vaccinex, Inc. (VCNX)
| Market Cap | 30.00M |
| Revenue (ttm) | 50,000 |
| Net Income (ttm) | -19.37M |
| Shares Out | 49.88M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,686 |
| Open | 0.568 |
| Previous Close | 0.590 |
| Day's Range | 0.568 - 0.620 |
| 52-Week Range | 0.410 - 2.280 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 29, 2023 |
About VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phas... [Read more]
Financial Performance
In 2021, Vaccinex's revenue was $900,000, an increase of 44.00% compared to the previous year's $625,000. Losses were -$22.38 million, -22.43% less than in 2020.
Financial StatementsNews
The 3 Best Biotech Stocks Under $1 to Buy for January
While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex's ActivMAb® Antibody Discovery Platform Surface Oncology initiates clinical trial with antibody discovered using Vacci...
Vaccinex Announces $3.8 Million Private Placement
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative d...
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
Continued Progress in Pepinemab Oncology and Neurology Clinical Programs Continued Progress in Pepinemab Oncology and Neurology Clinical Programs
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combinat...
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Vaccinex, Inc.'s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington's Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation
Data suggest that pepinemab slows or prevents cognitive decline in Huntington's Disease (HD)
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative d...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative di...
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
Excellent Progress in Pepinemab Clinical Programs
Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery
ActivMAb technology to generate Complex Membrane Antigen Virus is a valuable drug discovery tool for difficult-to-drug targets ActivMAb technology to generate Complex Membrane Antigen Virus is a valua...
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC);
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative ...
Vaccinex, Inc. to Present at CHDI's 17th Annual HD Therapeutics Conference Meeting
Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022 Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wed...
Vaccinex And 4 Other Penny Stocks Bought By Insiders
The unemployment rate in the Eurozone dropped to a record low of 7% in December from a revised 7.1% level in the previous month, helping the STOXX Europe 600 Index record gains this morning. Investors...
Vaccinex Announces $6.6 Million Private Placement
Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022
Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer
Vaccinex Inc shares are gaining after the Company reported interim response data in the Phase Ib segment of the KEYNOTE-B84 study.
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer ...
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
Phase 1b segment evaluated safety and tolerability of the combination
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
In-person and virtual Presentation: November 10-14th, 2021 In-person and virtual Presentation: November 10-14th, 2021
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer's Disease (CTAD) Meeting
Live Presentation: Thursday, Nov. 11, 2021 Live Presentation: Thursday, Nov. 11, 2021
Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Enrollment underway in combination Phase 1b/2 study of pepinemab with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
Virtual Dates: November 18 th – 19 th , 2021
Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021
Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntington's Disease (HD) trial suggesting a cognitive benefit in patients with mildly advanced disease Presentation...
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and...